Previous close | 285.40 |
Open | 285.40 |
Bid | 280.00 x 0 |
Ask | 280.20 x 0 |
Day's range | 278.40 - 287.00 |
52-week range | 189.03 - 302.00 |
Volume | |
Avg. volume | 552,496 |
Market cap | 95.163B |
Beta (5Y monthly) | 0.26 |
PE ratio (TTM) | 44.37 |
EPS (TTM) | 6.31 |
Earnings date | 16 Jul 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 344.80 |
Sobi® today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion recommending approval of efanesoctocog alfa, for the treatment and prevention of bleeds and perioperative prophylaxis in haemophilia A. Efanesoctocog alfa is a once-weekly and high-sustained factor VIII replacement therapy for patients of all ages and any disease severity.
Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the first quarter 2024
The shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg. No. 556038-9321, are hereby summoned to the Annual General Meeting (the "Meeting"), to be held on Tuesday, 14 May 2024 at 15.00 at IVA Konferenscenter, Grev Turegatan 16, Stockholm, Sweden.